Claims
- 1. A method of delivering a substance to a subject, the method comprising:
administering to a subject a non-polymeric hematopoeitic cell clot containing a substance to deliver the substance to the subject.
- 2. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot comprises bone marrow cells.
- 3. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot comprises blood cells.
- 4. The method according to claim 1, wherein the substance comprises a gene transfer vehicle.
- 5. The method according to claim 1, wherein the substance comprises additional cells.
- 6. The method according to claim 5, wherein the additional cells comprise genetically engineered cells.
- 7. The method according to claim 5, wherein the additional cells comprise naïve cells.
- 8. The method according to claim 1, wherein the substance comprises proteins.
- 9. The method according to claim 1, wherein the substance comprises recombinant proteins.
- 10. The method according to claim 1, wherein the substance comprises soluble proteins.
- 11. The method according to claim 1, wherein the substance comprises bioactive molecules.
- 12. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is delivered into bone.
- 13. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is delivered into soft tissues.
- 14. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is delivered into at least one of cartilage, ligaments, tendons, meniscuses and invertebral discs.
- 15. The method according to claim 1, wherein the shape and size of the non-polymeric hematopoeitic cell clot is determined by a mold.
- 16. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is homogenized with the substance.
- 17. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is genetically modified to express at least one of growth factors and other gene products that facilitate tissue repair.
- 18. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot has a volume that is determined by the size of a tissue to be repaired.
- 19. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is collected from a subject.
- 20. The method according to claim 2, wherein the bone marrow cells are harvested from iliac crests.
- 21. The method according to claim 2, wherein the bone marrow cells are harvested from osteochondral defects that expose underlying bone marrow.
- 22. The method according to claim 1, wherein the substrate is in the form of a solution.
- 23. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot containing substance is titrated.
- 24. The method according to claim 23, wherein the titration is performed using a pipette.
- 25. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is mixed with a suspension of at least one of naïve and genetically modified cells, forming a cell suspension.
- 26. The method according to claim 25, wherein the cell suspension contains at least one gene vector.
- 27. The method according to claim 25, wherein the cell suspension contains no additional gene vectors.
- 28. A method according to claim 1, wherein the delivery is a slow, localized release of the substance from the non-polymeric hematopoeitic cell clot.
- 29. A method according to claim 1, wherein the non-polymeric hematopoeitic cell clot is shaped in a way to allow an effective delivery of the substance.
- 30. A method according to claim 1, further comprising regenerating tissue in the area of substance delivery.
- 31. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot produced from a sample of hematopoeitic cells which is allowed to clot for 15-30 minutes.
- 32. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot produced from a sample of hematopoeitic cells which is allowed to clot at room temperature.
- 33. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot produced from a sample of hematopoeitic cells which is placed in a vessel to clot.
- 34. The method according to claim 33, wherein the non-polymeric hematopoeitic cell clot is harvested from the vessel.
- 35. The method according to claim 1, wherein the non-polymeric hematopoeitic cell clot produced from a sample of hematopoeitic cells which is washed in a Phosphate Buffer Saline.
- 36. The method according to claim 1, wherein any unbound substance is removed from the non-polymeric hematopoeitic cell clot.
- 37. A method of preparing a non-polymeric hematopoeitic cell clot substance delivery system, the method comprising:
adding a substance to a sample of hematopoeitic cells; and allowing the sample of hematopoeitic cells containing the substance to form a non-polymeric hematopoeitic cell clot.
- 38. A method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is implanted into a subject.
- 39. A method according to claim 37, wherein the substance is delivered to the subject.
- 40. A method according to claim 39, wherein the delivery is a slow, localized release of the substance from the non-polymeric hematopoeitic cell clot.
- 41. A method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is shaped in a way to allow an effective delivery of the substance.
- 42. A method according to claim 37, wherein the non-polymeric hematopoeitic cell clot delivery system is used to regenerate tissue.
- 43. A method according to claim 37, wherein the sample of hematopoeitic cells is collected from a subject.
- 44. A method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is formed in a vessel.
- 45. A method according to claim 44, further comprising harvesting the non-polymeric hematopoeitic cell clot from the vessel.
- 46. A method according to claim 37, further comprising washing the non-polymeric hematopoeitic cell clot.
- 47. A method according to claim 46, wherein any unbound substance is removed by washing.
- 48. A method according to claim 46, wherein the non-polymeric hematopoeitic cell clot is washed in a Phosphate Buffer Saline.
- 49. The method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is allowed to clot for 15-30 minutes.
- 50. The method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is allowed to clot at room temperature.
- 51. The method according to claim 37, wherein the hematopoeitic cells comprise bone marrow cells.
- 52. The method according to claim 37, wherein the hematopoeitic cells comprise blood cells.
- 53. The method according to claim 37, wherein the substance comprises a gene transfer vehicle.
- 54. The method according to claim 37, wherein the substance comprises additional cells.
- 55. The method according to claim 54, wherein the additional cells comprise genetically engineered cells.
- 56. The method according to claim 54, wherein the additional cells comprise naïve cells.
- 57. The method according to claim 37, wherein the substance comprises proteins.
- 58. The method according to claim 37, wherein the substance comprises recombinant proteins.
- 59. The method according to claim 37, wherein the substance comprises soluble proteins.
- 60. The method according to claim 37, wherein the substance comprises bioactive molecules.
- 61. The method according to claim 38, wherein the non-polymeric hematopoeitic cell clot is delivered into bone.
- 62. The method according to claim 38, wherein the non-polymeric hematopoeitic cell clot is delivered into soft tissues.
- 63. The method according to claim 38, wherein the non-polymeric hematopoeitic cell clot is delivered into at least one of cartilage, ligaments, tendons, meniscuses and invertebral discs.
- 64. The method according to claim 37, wherein the shape and size of the non-polymeric hematopoeitic cell clot is determined by a mold.
- 65. The method according to claim 37, wherein the non-polymeric hematopoeitic cell clot is homogenized with the substance.
- 66. The method according to claim 37, wherein the hematopoeitic cells are genetically modified to express at least one of growth factors and other gene products that facilitate tissue repair.
- 67. The method according to claim 37, wherein the non-polymeric hematopoeitic cell clot has a volume that is determined by the size of a tissue to be repaired.
- 68. The method according to claim 51, wherein the bone marrow cells are harvested from iliac crests.
- 69. The method according to claim 51, wherein the bone marrow cells are harvested from osteochondral defects that expose underlying bone marrow.
- 70. The method according to claim 37, wherein the substance is in the form of a solution.
- 71. The method according to claim 37, wherein the non-polymeric hematopoeitic cell clot containing substance is titrated.
- 72. The method according to claim 71, wherein the titration is performed using a pipette.
- 73. The method according to claim 37, wherein the hematopoeitic cells are mixed with a suspension of at least one of naïve and genetically modified cells, forming a cell suspension.
- 74. The method according to claim 73, wherein the cell suspension contains at least one gene vector.
- 75. The method according to claim 73, wherein the cell suspension contains no additional gene vectors.
- 76. A substance delivery system comprising:
a non-polymeric hematopoeitic cell clot having a substance incorporated therein.
- 77. A substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is shaped in a way to allow an effective delivery of the substance.
- 78. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot comprises bone marrow cells.
- 79. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot comprises blood cells.
- 80. The substance delivery system according to claim 76, wherein the substance comprises a gene transfer vehicle.
- 81. The substance delivery system according to claim 76, wherein the substance comprises additional cells.
- 82. The substance delivery system according to claim 81, wherein the additional cells comprise genetically engineered cells.
- 83. The substance delivery system according to claim 81, wherein the additional cells comprise naïve cells.
- 84. The substance delivery system according to claim 81, wherein the substance comprises proteins.
- 85. The substance delivery system according to claim 81, wherein the substance comprises recombinant proteins.
- 86. The substance delivery system according to claim 76, wherein the substance comprises soluble proteins.
- 87. The substance delivery system according to claim 76, wherein the substance comprises bioactive molecules.
- 88. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is formulated for delivery into bone.
- 89. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is formulated for delivery into soft tissues.
- 90. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is formulated for delivery into at least one of cartilage, ligaments, tendons, meniscuses and invertebral discs.
- 91. The substance delivery system according to claim 76, wherein the shape and size of the non-polymeric hematopoeitic cell clot is determined by a mold.
- 92. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is homogenized with the substance.
- 93. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is genetically modified to express at least one of growth factors and other gene products that facilitate tissue repair.
- 94. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot has a volume that is determined by the size of a tissue to be repaired.
- 95. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared from an isolated sample of hematopoeitic cells.
- 96. The substance delivery system according to claim 78, wherein the bone marrow cells are isolated from iliac crest bone marrow cells.
- 97. The substance delivery system according to claim 78, wherein the bone narrow cells are isolated from osteochondral defects that expose underlying bone marrow.
- 98. The substance delivery system according to claim 76, wherein the substance is at least one of naïve and genetically modified cells.
- 99. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared by the process of allowing a sample of hematopoeitic cells to clot for 15-30 minutes.
- 100. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared by the process of allowing a sample of hematopoeitic cells to clot at room temperature.
- 101. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared by the process of allowing a sample of hematopoeitic cells to clot in a vessel.
- 102. The substance delivery system according to claim 101, further comprising harvesting the non-polymeric hematopoeitic cell clot from the vessel.
- 103. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared by the process of washing the non-polymeric hematopoeitic cell clot in a Phosphate Buffer Saline.
- 104. The substance delivery system according to claim 76, wherein the non-polymeric hematopoeitic cell clot is prepared by the process of removing any unbound substance from the non-polymeric hematopoeitic cell clot.
RELATED APPLICATIONS
[0001] This application claims the benefit of co-pending U.S. Provisional Patent Application Serial No. 60/386,870, filed Jun. 6, 2002, which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60386870 |
Jun 2002 |
US |